A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer

Lilly

Status and phase: Completed; Phase 2

Conditions: Pancreatic Cancer

Treatments: Drug: placebo; Drug: Gemcitabine; Drug: LY293111

Study type: Interventional

Funder types: Industry

Identifiers

NCT00055250

H6H-MC-JEAL

4840

Details and patient eligibility

About

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adenocarcinoma of the pancreas that is locally advanced or metastatic and not amenable to resection with curative intent
• Tumor that can be measured by x-ray or scan
• Adequate organ function

Exclusion criteria

• Inability to swallow capsules
• Documented brain metastases
• Prior chemotherapy or biological therapy for this disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind